The rationale for SB939 treatment in translocation-associated sarcomas is perhaps the best explained in the synovial sarcoma, where fusions of the SS18 and SSX (1, 2 and 4) genes are characteristic. This evidence concerns the gene SS18 and synovial sarcoma.